Noemi Mergen

1.4k total citations · 1 hit paper
13 papers, 687 citations indexed

About

Noemi Mergen is a scholar working on Public Health, Environmental and Occupational Health, Oncology and Genetics. According to data from OpenAlex, Noemi Mergen has authored 13 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Public Health, Environmental and Occupational Health, 10 papers in Oncology and 5 papers in Genetics. Recurrent topics in Noemi Mergen's work include Acute Lymphoblastic Leukemia research (11 papers), CAR-T cell therapy research (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Noemi Mergen is often cited by papers focused on Acute Lymphoblastic Leukemia research (11 papers), CAR-T cell therapy research (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Noemi Mergen collaborates with scholars based in Germany, United States and Italy. Noemi Mergen's co-authors include Gerhard Zugmaier, Albrecht Reichle, Max S. Topp, Ralf C. Bargou, Christoph Faul, Heinz‐August Horst, Matthias Stelljes, Andreas Viardot, Svenja Neumann and Petra Klappers and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biology of Blood and Marrow Transplantation.

In The Last Decade

Noemi Mergen

12 papers receiving 669 citations

Hit Papers

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
    2014 488 citations Max S. Topp, Nicola Gökbuget et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noemi Mergen Germany 8 503 375 195 186 135 13 687
Hendrik Wessels Germany 5 401 0.8× 387 1.0× 275 1.4× 149 0.8× 113 0.8× 14 644
Sara Raponi Italy 15 244 0.5× 179 0.5× 225 1.2× 215 1.2× 231 1.7× 24 626
Evelyn Degenhard Germany 4 326 0.6× 133 0.4× 75 0.4× 90 0.5× 142 1.1× 4 412
Sameh Gaballa United States 12 169 0.3× 87 0.2× 269 1.4× 87 0.5× 98 0.7× 55 413
Maria Cristina Puzzolo Italy 6 160 0.3× 277 0.7× 260 1.3× 63 0.3× 41 0.3× 7 437
Houston Holmes United States 12 319 0.6× 82 0.2× 202 1.0× 146 0.8× 119 0.9× 39 540
Marie-Elisabeth Goebeler Germany 6 324 0.6× 74 0.2× 41 0.2× 197 1.1× 110 0.8× 7 392
A.M. Ford United Kingdom 8 125 0.2× 138 0.4× 133 0.7× 88 0.5× 215 1.6× 10 448
Michael Starck Germany 8 219 0.4× 330 0.9× 241 1.2× 70 0.4× 79 0.6× 12 493
Pramoda Challagundla United States 10 223 0.4× 154 0.4× 168 0.9× 356 1.9× 346 2.6× 15 742

Countries citing papers authored by Noemi Mergen

Since Specialization
Citations

This map shows the geographic impact of Noemi Mergen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noemi Mergen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noemi Mergen more than expected).

Fields of papers citing papers by Noemi Mergen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noemi Mergen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noemi Mergen. The network helps show where Noemi Mergen may publish in the future.

Co-authorship network of co-authors of Noemi Mergen

This figure shows the co-authorship network connecting the top 25 collaborators of Noemi Mergen. A scholar is included among the top collaborators of Noemi Mergen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noemi Mergen. Noemi Mergen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Locatelli, Franco, Gerhard Zugmaier, Noemi Mergen, et al.. (2022). Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Advances. 6(3). 1004–1014. 36 indexed citations
2.
Giri, Pratyush, Sushrut Patil, H. Miles Prince, et al.. (2022). Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 40(16_suppl). e19584–e19584. 7 indexed citations
3.
Locatelli, Franco, Gerhard Zugmaier, Noemi Mergen, et al.. (2021). Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer Journal. 11(2). 28–28. 1 indexed citations
4.
Locatelli, Franco, Gerhard Zugmaier, Noemi Mergen, et al.. (2020). Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO). Blood. 136(Supplement 1). 24–25. 1 indexed citations
5.
Coyle, Luke, Nicholas Morley, Alessandro Rambaldi, et al.. (2020). Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood. 136(Supplement 1). 14–15. 2 indexed citations
6.
Gökbuget, Nicola, Gerhard Zugmaier, Hervé Dombret, et al.. (2020). Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leukemia & lymphoma. 61(11). 2665–2673. 54 indexed citations
7.
8.
Gore, Lia, Franco Locatelli, Gerhard Zugmaier, et al.. (2014). Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood. 124(21). 3703–3703. 19 indexed citations
9.
10.
Topp, Max S., Nicola Gökbuget, Gerhard Zugmaier, et al.. (2014). Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 32(36). 4134–4140. 488 indexed citations breakdown →
11.
Topp, Max S., Nicola Goekbuget, Gerhard Zugmaier, et al.. (2012). Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL.. Journal of Clinical Oncology. 30(15_suppl). 6500–6500. 15 indexed citations
12.
13.
Topp, Max S., Nicola Goekbuget, Gerhard Zugmaier, et al.. (2011). Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial. Blood. 118(21). 252–252. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hendrik Wessels Breakdown of academic impact, for papers by Sara Raponi Breakdown of academic impact, for papers by Evelyn Degenhard Breakdown of academic impact, for papers by Sameh Gaballa Breakdown of academic impact, for papers by Maria Cristina Puzzolo Breakdown of academic impact, for papers by Houston Holmes Breakdown of academic impact, for papers by Marie-Elisabeth Goebeler Breakdown of academic impact, for papers by A.M. Ford Breakdown of academic impact, for papers by Michael Starck Breakdown of academic impact, for papers by Pramoda Challagundla
Rankless by CCL
2026